The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
The facility is expected to be completed in 2024
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
Subscribe To Our Newsletter & Stay Updated
